Key result
Higher baseline platelet count (>350×10^9/L) significantly increased the relative risk of major adverse cardiac events (RR 1.63) at 1-month follow-up compared to lower platelet count (<150×10^9/L) in patients with acute coronary syndrome.
Why the study?
Does higher baseline platelet count increase the risk of mortality and MACE in patients with acute coronary syndrome?
Meta-Analysis (n=39,324)
Yes
Does higher baseline platelet count increase the risk of mortality and MACE in patients with acute coronary syndrome?
Effect estimate: RR 1.63 (95% CI 1.25-2.13)
p-value: p=<0.001
Higher baseline platelet count is associated with an increased risk of mortality and MACE in patients with acute coronary syndrome.
No takes yet. Share an insight, caveat, or question.
May warrant closer monitoring in high-platelet ACS; leaves open whether count should guide therapy.
Wu et al. (2012) conducted a meta-analysis in Acute Coronary Syndrome (ACS) (n=39,324). Upper Platelet Count (>350×10^9/L) vs. Bottom Platelet Count (<150×10^9/L) was evaluated on Major adverse cardiac events (MACE) at 1-month follow-up (RR 1.63, 95% CI 1.25-2.13, p=<0.001). Higher baseline platelet count (>350×10^9/L) significantly increased the relative risk of major adverse cardiac events (RR 1.63) at 1-month follow-up compared to lower platelet count (<150×10^9/L) in patients with acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: